NTRK1 and neoplasm: Based on the analysis results, we further demonstrated that the high-risk IA subgroup was sensitive to drugs related to classical tumor driver pathways, such as the p53 pathway and receptor tyrosine kinase (RTK) pathway (Fig. 5D).